DURHAM, N.C., United States and BEIJING, China – April 1, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conferences in April 2022. Details of the conferences and management presentations are as follows:

Nomura Virtual Private and New IPO Company Corporate Day 2022

Investor Meetings: April 12-13, 2022

Participants: Management team and IR

For more information, please contact your Nomura representative.

UBS Asia Healthcare Virtual Conference 2022

Investor Meetings: April 28-29, 2022

Participants: Management team and IR

For more information, please contact your UBS representative.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

Media Inquiry:

media@briibio.com
Summer Li (China)
+86-135-2191-1607
Ben Shannon (U.S.)
+1-919-360-3039

Investor Inquiry:
ir@briibio.com
Chris Fang
+86-139-1692-8049